While the most pronounced weight loss with GLP-1RA therapy tends to occur within the first 6 months of treatment, continued use is generally associated with maintenance or further incremental weight loss
Karen Tang, author of Its Not Hysteria and founder of Thrive Gynecology, told Flow Space
Tirzepatide: a Two-Pronged Attack A new player called tirzepatide joined the GLP-1 receptor agonist game in 2022
A phase II randomized clinical trial of a nutritional formulation for cognition and mood in Alzheimer's disease
One of the future challenges is ensuring that the manufactures can keep up with the ongoing demand for the available technology
Let's hope Teva comes up with a cool name for this one #obesity #diabetes #biosimilar #generic #biotechindustry #pharma Thanks for sharing, it will be interesting to see if cost is prioritized over efficacy and convenience, and how Teva positions its daily Saxenda generic in a market dominated by next-gen weekly GLP-1s